AI assistant
Pfizer Ltd. — Regulatory Filings 2022
Nov 25, 2022
60507_rns_2022-11-25_aa43b322-8092-4a17-8774-d7062ff55a4a.pdf
Regulatory Filings
Open in viewerOpens in your device viewer
==> picture [100 x 42] intentionally omitted <==
Pfizer Limited
The Capital, 1802/1901, Plot No. C - 70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400 051. Tel : +91 22 6693 2000 Fax : +91 22 2654 0274
November 25, 2022
The Corporate Relationship Dept. The Manager, Listing Dept. BSE Limited The National Stock Exchange of India Ltd. 1st Floor, P.J.Towers Exchange Plaza, 5[th] Floor, Dalal Street, Fort Plot No. C/1, G Block Mumbai – 400 001 Bandra-Kurla Complex, Bandra (E) Scrip Code: 500680 Mumbai – 400 051 Scrip Symbol: PFIZER
Dear Sirs,
Sub: Disclosure under Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘Listing Regulations’)
Pursuant to Regulation 23(9) of the Listing Regulations, please find enclosed, disclosure of related party transactions on a consolidated basis, in the format specified in the accounting standards for the half year ended September 30, 2022.
The said disclosure is also available on the website of the Company i.e., www.pfizerltd.co.in
Please take the above on record
Thanking you,
Yours truly,
For Pfizer Limited
==> picture [98 x 19] intentionally omitted <==
----- Start of picture text ----- PRAJEET----- End of picture text -----
NAIR
Digitally signed by PRAJEET NAIR DN: c=IN, o=Personal, 2.5.4.20=9933a48702916ad69ca05ea07b057e4a4737e501e6 5094b9d54663b70517bbe5, postalCode=400054, st=MAHARASHTRA, serialNumber=c24aea3eb0ba76c8cf19782a6242b9b35252d6 b9461f59c3998022881b762db1, cn=PRAJEET NAIR, l=MUMBAI, title=7345, pseudonym=734520210415120738822, email=[email protected] Date: 2022.11.25 16:19:07 +05'30'
Prajeet Nair Director – Corporate Services & Company Secretary
Encl.: A/a
CIN: L24231MH1950PLC008311 Email ID: [email protected] Website: www.pfizerltd.co.in
Pfizer Limited - Statement of Related Party Transactions pursuant to Regulation 23(9) of SEBI (LODR), 2015 for the half year ended September 30, 2022.
| Sr.no | Details oflisted entittransactio | the partyy entering into then | Details of the c | ounter party | Type of related party trans | action | Value of the related partytransaction as approvedby the audit committee | Remarks on approval by AuditCommittee | Value of transactionduring the reportingperiod | In case monies are due to either partyas a result of the transaction | |||
| Name | PAN | Name | Relationship of the counterparty with | Opening balance | Closing balance | ||||||||
| the listed entity or its subsidiary | |||||||||||||
| 1 | Pfizer Limi | ted | AAACP3334M | Pfizer Service C | ompany BVBA, Belgium | Fellow subsidiary | Purchase of goods or servic | es | 238.28 | On arm's length basis and inOrdinary course of business | 238.28 | 81.60 | 33.53 |
| 2 | Pfizer Limi | ted | AAACP3334M | Pfizer Healthca | re India Private Limited | Fellow subsidiary | Service Income | 1.97 | On arm's length basis and inOrdinary course of business | 1.97 | 5.74 | -1.97 | |
| 3 | Pfizer Limi | ted | AAACP3334M | Pfizer Products | India Private Limited | Fellow subsidiary | Service Income | 9.14 | On arm's length basis and inOrdinary course of business | 9.14 | -3.90 | -10.02 | |
| 4 | Pfizer Limi | ted | AAACP3334M | Pfizer Export B. | V. | Fellow subsidiary | Service Income | 0.32 | On arm's length basis and inOrdinary course of business | 0.32 | -2.05 | -0.32 | |
| 5 | Pfizer Limi | ted | AAACP3334M | Pfizer Worldwi | de Services Company | Fellow subsidiary | Service Income | 28.74 | On arm's length basis and inOrdinary course of business | 28.74 | -13.03 | -33.27 | |
| 6 | Pfizer Limi | ted | AAACP3334M | Pfizer Corporat | ion Hong Kong Limited | Fellow subsidiary | Re-imbursement of Expens | e | 0.01 | On arm's length basis and inOrdinary course of business | 0.01 | 0.00 | 0.01 |
| 7 | Pfizer Limi | ted | AAACP3334M | Pfizer Overseas | LLC | Fellow subsidiary | Inter Company Write Back | 0.25 | On arm's length basis and inOrdinary course of business | 0.25 | 0.35 | - | |
| 8 | Pfizer Limi | ted | AAACP3334M | Pfizer Products | India Private Limited | Fellow subsidiary | Recovery of Expenses | 0.17 | On arm's length basis and inOrdinary course of business | 0.17 | - | - | |
| 9 | Pfizer Limi | ted | AAACP3334M | John Wyeth & | Brother Ltd | Company collectively exercisingsignificant influence | Dividend paid | 5.73 | On arm's length basis and inOrdinary course of business | 5.73 | 2.44 | 2.50 | |
| 10 | Pfizer Limi | ted | AAACP3334M | Parke, Davis & | Company LLC | Fellow subsidiary | Dividend paid | 6.21 | On arm's length basis and inOrdinary course of business | 6.21 | - | - | |
| 11 | Pfizer Limi | ted | AAACP3334M | Pfizer East India | BV | Fellow subsidiary | Dividend paid | 118.21 | On arm's length basis and inOrdinary course of business | 118.21 | - | - | |
| 12 | Pfizer Limi | ted | AAACP3334M | Pharmacia LLC | Fellow subsidiary | Dividend paid | 5.10 | On arm's length basis and inOrdinary course of business | 5.10 | - | - | ||
| 13 | Pfizer Limi | ted | AAACP3334M | Warner-Lambe | rt Company LLC | Fellow subsidiary | Dividend paid | 7.72 | On arm's length basis and inOrdinary course of business | 7.72 | - | - | |
| 14 | Pfizer Limi | ted | AAACP3334M | Wyeth Holding | s LLC | Fellow subsidiary | Dividend paid | 10.60 | On arm's length basis and inOrdinary course of business | 10.60 | - | - | |
| 15 | Pfizer Limi | ted | AAACP3334M | Wyeth LLC | Fellow subsidiary | Dividend paid | 36.52 | On arm's length basis and inOrdinary course of business | 36.52 | - | - | ||
| 20 | Pfizer Limi | ted | AAACP3334M | Mr. Pradip Sha | h | Independent Director | Sitting Fees | 0.04 | On arm's length basis and inOrdinary course of business | 0.04 | - | - | |
| 21 | Pfizer Limited | AAACP3334M | Mr. Uday Khanna | Independent Director | Sitting Fees | 0.03 | On arm's length basis and inOrdinary course of business | 0.03 | - | - |
|---|---|---|---|---|---|---|---|---|---|---|
| 22 | Pfizer Limited | AAACP3334M | Mr. Sunil Lalbhai | Independent Director | Sitting Fees | 0.03 | On arm's length basis and inOrdinary course of business | 0.03 | - | - |
| 23 | Pfizer Limited | AAACP3334M | Ms. Meena Ganesh | Independent Director | Sitting Fees | 0.02 | On arm's length basis and inOrdinary course of business | 0.02 | - | - |
| 16 | Pfizer Limited | AAACP3334M | Mr. S. Sridhar | Key Managerial Personnel | Remuneration | 4.13 | On arm's length basis and inOrdinary course of business | 4.13 | - | - |
| 17 | Pfizer Limited | AAACP3334M | Mr. Milind Patil | Key Managerial Personnel | Remuneration | 2.15 | On arm's length basis and inOrdinary course of business | 2.15 | - | - |
| 18 | Pfizer Limited | AAACP3334M | Mr. Samir Kazi | Key Managerial Personnel | Remuneration | 1.42 | On arm's length basis and inOrdinary course of business | 1.42 | - | - |
| 19 | Pfizer Limited | AAACP3334M | Mr. Prajeet Nair | Key Managerial Personnel | Remuneration | 0.40 | On arm's length basis and inOrdinary course of business | 0.40 | - | - |